Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma

Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma Based on Tumor Immune Microenvironment

NCT07198802•Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

View on ClinicalTrials.gov

Summary

To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2\~3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.

Eligibility

Age

15 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Clearly diagnosed with nasopharyngeal carcinoma by pathology;
•2. Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital;
•3. Patients diagnosed in our hospital from January 2025 to December 2028;
•4. Have relatively complete clinical data;
•5. Age between 15 and 75 years old;

Exclusion Criteria

•1. The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.;
•2. The participants failed to obtain pathological and imaging data for various reasons;
•3. Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.

Key Dates

Start Date

October 1, 2025

Primary Completion Date

December 1, 2028

Completion Date

December 1, 2028

Last Updated

September 30, 2025

Enrollment

600

ESTIMATED participants

Conditions

Nasopharyngeal Carcinoma (NPC)

Interventions

No Intervention

OTHER

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

NCT07340515

Nasopharyngeal Carcinoma (NPC)

View study

RECRUITINGPHASE1/PHASE2

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC

NCT06982300

Nasopharyngeal Carcinoma (NPC)

View study

RECRUITINGPHASE2

Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

NCT07085988

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 30, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma

Inclusion Criteria

Exclusion Criteria

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC

Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas